Internal Medicine, Rheumatology · Birmingham, AL
NPI
1154426872
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2022 Brookwood Medical Center Drive, Suite 211
Birmingham, AL, 35209
Phone (205) 877-2955
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.3M
315,024 services
Medicare patients, 2024
659
Average age 73
Drug cost, 2024
$7.1M
13,640 prescriptions
Company payments, 2025
$4,571
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Greg E Eudy was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 134,400 times for 36 patients. In total Greg E Eudy billed 315,024 services in 33 codes, and Medicare paid $4.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 134,400 | 36 | $3.58 | $482K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 54,976 | 73 | $33.77 | $1.9M |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 26,376 | 29 | $9.11 | $240K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 23,520 | 17 | $8.52 | $200K |
| J0897 Injection, denosumab, 1 mg | Office | 22,500 | 211 | $20.57 | $463K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,596 | 12 | $24.99 | $115K |
| 99214 Office E&M - Established | Office | 1,259 | 585 | $80.70 | $102K |
| 96413 Chemotherapy Administration | Office | 1,139 | 152 | $84.77 | $97K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 835 | 131 | $43.73 | $37K |
| 96401 Chemotherapy Administration | Office | 666 | 36 | $46.38 | $31K |
| 96372 Injection Administration | Office | 396 | 184 | $9.46 | $3,747 |
| J1201 Injection, cetirizine hydrochloride, 0.5 mg | Office | 341 | 13 | $11.66 | $3,976 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 200 | 31 | $0.07 | $13.63 |
| 96415 Chemotherapy Administration | Office | 157 | 27 | $18.46 | $2,899 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 144 | 24 | $0.61 | $87.21 |
By year: 2022 $3.9M for 235,194 services; 2023 $3.9M for 269,592 services; 2024 $4.3M for 315,024 services.
Medicare prescription drug claims, 2024
In 2024, the drug Greg E Eudy prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,729 prescriptions and refills. In total Greg E Eudy wrote 13,640 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,729 | 4,414 | 476 | $134K |
| Methotrexate Methotrexate Sodium | 862 | 1,870 | 244 | $31K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 806 | 807 | 103 | $21K |
| Tramadol Hcl Generic | 733 | 785 | 149 | $5,971 |
| Gabapentin Generic | 589 | 867 | 124 | $10K |
| Prednisone Generic | 562 | 726 | 128 | $5,240 |
| Celecoxib Generic | 466 | 1,078 | 136 | $30K |
| Duloxetine Hcl Generic | 376 | 921 | 98 | $13K |
| Meloxicam Generic | 356 | 875 | 109 | $2,170 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 346 | 346 | 37 | $13K |
| Pregabalin Generic | 290 | 348 | 48 | $6,534 |
| Sulfasalazine Dr Sulfasalazine | 248 | 492 | 65 | $12K |
| Cyclobenzaprine Hcl Generic | 234 | 404 | 64 | $1,912 |
| Sulfasalazine Generic | 232 | 466 | 60 | $8,862 |
| Allopurinol Generic | 207 | 555 | 58 | $2,174 |
Brand drugs: 2,069 claims; generic drugs: 11,457 claims; opioid claims: 2,167.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Greg E Eudy $4,571 ($4,571 in general payments such as food, travel and fees) from 25 companies. The largest payer was Abbvie Inc. with $823.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 35 | $823 |
| Pfizer Inc. PFE | 28 | $611 |
| Amgen Inc. AMGN | 28 | $546 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $414 |
| UCB, Inc. UCB.BR | 19 | $366 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $339 |
| E.R. Squibb & Sons, L.L.C. BMY | 14 | $330 |
| Janssen Biotech, Inc. JNJ | 10 | $215 |
| GlaxoSmithKline, LLC. GSK | 8 | $160 |
| Mallinckrodt Hospital Products Inc. | 5 | $128 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.